Basit öğe kaydını göster

dc.contributor.authorShahbazi, Reza
dc.contributor.authorOzpolat, Bulent
dc.contributor.authorUlubayram, Kezban
dc.date.accessioned2019-12-16T09:57:14Z
dc.date.available2019-12-16T09:57:14Z
dc.date.issued2016
dc.identifier.issn1743-5889
dc.identifier.urihttps://doi.org/10.2217/nnm-2016-0035
dc.identifier.urihttp://hdl.handle.net/11655/19853
dc.description.abstractTheranostic approaches, combining the functionality of both therapy and imaging, have shown potential in cancer nanomedicine. Oligonucleotides such as small interfering RNA and microRNA, which are powerful therapeutic agents, have been effectively employed in theranostic systems against various cancers. Nanoparticles are used to deliver oligonucleotides into tumors by passive or active targeting while protecting the oligonucleotides from nucleases in the extracellular environment. The use of quantum dots, iron oxide nanoparticles and gold nanoparticles and tagging with contrast agents, like fluorescent dyes, optical or magnetic agents and various radioisotopes, has facilitated early detection of tumors and evaluation of therapeutic efficacy. In this article, we review the advantages of theranostic applications in cancer therapy and imaging, with special attention to oligonucleotide-based therapeutics.
dc.language.isoen
dc.publisherFuture Medicine Ltd
dc.relation.isversionof10.2217/nnm-2016-0035
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectBiotechnology & Applied Microbiology
dc.subjectScience & Technology - Other Topics
dc.titleOligonucleotide-Based Theranostic Nanoparticles In Cancer Therapy
dc.typeinfo:eu-repo/semantics/review
dc.relation.journalNanomedicine
dc.contributor.departmentNanoteknoloji ve Nanotıp
dc.identifier.volume11
dc.identifier.issue10
dc.identifier.startpage1287
dc.identifier.endpage1308
dc.description.indexWoS


Bu öğenin dosyaları:

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster